Literature DB >> 27746961

SBRT versus lobectomy in stage I NSCLC: knowns, unknowns and its interpretation.

Matthias Guckenberger1.   

Abstract

Year:  2016        PMID： 27746961      PMCID： PMC5059340          DOI： 10.21037/jtd.2016.08.59

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  27 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.

Authors:  Sashendra Senthi; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Lancet Oncol       Date:  2012-06-22       Impact factor: 41.316

3.  A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.

Authors:  Inga Siiner Grills; Andrew J Hope; Matthias Guckenberger; Larry L Kestin; Maria Werner-Wasik; Di Yan; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Juergen Wilbert; Ying Xiao; Jose Belderbos
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

4.  Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly.

Authors:  Shervin M Shirvani; Jing Jiang; Joe Y Chang; James W Welsh; Daniel R Gomez; Stephen Swisher; Thomas A Buchholz; Benjamin D Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-09-11       Impact factor: 7.038

5.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.

Authors:  Yasushi Nagata; Kenji Takayama; Yukinori Matsuo; Yoshiki Norihisa; Takashi Mizowaki; Takashi Sakamoto; Masato Sakamoto; Michihide Mitsumori; Keiko Shibuya; Norio Araki; Shinsuke Yano; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-19       Impact factor: 7.038

6.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

7.  Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.

Authors:  Shervin M Shirvani; Jing Jiang; Joe Y Chang; James Welsh; Anna Likhacheva; Thomas A Buchholz; Stephen G Swisher; Benjamin D Smith
Journal:  JAMA Surg       Date:  2014-12       Impact factor: 14.766

8.  Prediction of Early Death in Patients with Early-Stage NSCLC-Can We Select Patients without a Potential Benefit of SBRT as a Curative Treatment Approach?

Authors:  Rainer J Klement; José Belderbos; Inga Grills; Maria Werner-Wasik; Andrew Hope; Meredith Giuliani; Hong Ye; Jan-Jakob Sonke; Heike Peulen; Matthias Guckenberger
Journal:  J Thorac Oncol       Date:  2016-04-07       Impact factor: 15.609

9.  Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer.

Authors:  Neil Kopek; Merete Paludan; Jørgen Petersen; Anders Traberg Hansen; Cai Grau; Morten Høyer
Journal:  Radiother Oncol       Date:  2009-06-24       Impact factor: 6.280

10.  Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial.

Authors:  Alexander V Louie; Erik van Werkhoven; Hanbo Chen; Egbert F Smit; Marinus A Paul; Joachim Widder; Harry J M Groen; Ben E E M van den Borne; Katrien De Jaeger; Ben J Slotman; Suresh Senan
Journal:  Radiother Oncol       Date:  2015-10       Impact factor: 6.280
View more
  3 in total

Review 1.  Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review.

Authors:  Salvatore Cozzi; Emanuele Alì; Lilia Bardoscia; Masoumeh Najafi; Andrea Botti; Gladys Blandino; Lucia Giaccherini; Maria Paola Ruggieri; Matteo Augugliaro; Federico Iori; Angela Sardaro; Cinzia Iotti; Patrizia Ciammella
Journal:  Cancers (Basel)       Date:  2022-05-28       Impact factor: 6.575

Review 2.  Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances.

Authors:  Nikhil T Sebastian; Meng Xu-Welliver; Terence M Williams
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  Three discipline collaborative radiation therapy (3DCRT) special debate: I would treat all early-stage NSCLC patients with SBRT.

Authors:  Pranshu Mohindra; Amit Sawant; Robert J Griffin; Narottam Lamichhane; Erina Vlashi; Meng Xu-Welliver; Michael Dominello; Michael C Joiner; Jay Burmeister
Journal:  J Appl Clin Med Phys       Date:  2019-02-22       Impact factor: 2.102
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.